Fidelity Investments
CRVS icon

Fidelity Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

Fidelity Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.2K Sell
2,356
-1,205
-34% -$16.7K ﹤0.01% 4452
2026
Q1 		$52.1K Buy
3,561
+1,270
+55% +$20.3K ﹤0.01% 4119
2025
Q4 		$17.6K Buy
2,291
+819
+56% +$6.46K ﹤0.01% 4519
2025
Q3 		$10.9K Buy
1,472
+1,238
+529% +$6.34K ﹤0.01% 4584
2025
Q2 		$937 Buy
234
+229
+4,580% +$833 ﹤0.01% 4975
2025
Q1 		$17 Hold
5
– – ﹤0.01% 5229
2024
Q4 		$29 Sell
5
-5
-50% -$37 ﹤0.01% 5287
2024
Q3 		$51 Sell
10
-43
-81% -$154 ﹤0.01% 5174
2024
Q2 		$96 Buy
53
+36
+212% +$67 ﹤0.01% 4978
2024
Q1 		$30 Buy
+17
New +$36 ﹤0.01% 5108
2023
Q4 		– Sell
-1,101
Closed -$1.61K – 5470
2023
Q3 		$1.61K Buy
+1,101
New +$2.33K ﹤0.01% 4586
2020
Q2 		– Sell
-400
Closed -$1K – 3657
2020
Q1 		$1K Buy
+400
New +$1.62K ﹤0.01% 3473
2019
Q4 		– Sell
-426,656
Closed -$1.28M – 3838
2019
Q3 		$1.28M Sell
426,656
-151,200
-26% -$635K ﹤0.01% 2378
2019
Q2 		$2.16M Sell
577,856
-267,700
-32% -$1.05M ﹤0.01% 2308
2019
Q1 		$3.4M Sell
845,556
-195,700
-19% -$826K ﹤0.01% 2181
2018
Q4 		$3.82M Sell
1,041,256
-977,556
-48% -$6.67M ﹤0.01% 2120
2018
Q3 		$17.3M Sell
2,018,812
-459,485
-19% -$4.59M ﹤0.01% 1737
2018
Q2 		$27.2M Sell
2,478,297
-73,823
-3% -$824K ﹤0.01% 1579
2018
Q1 		$29.4M Buy
2,552,120
+1,276,470
+100% +$12.1M ﹤0.01% 1539
2017
Q4 		$13.2M Buy
1,275,650
+421,139
+49% +$5.39M ﹤0.01% 1864
2017
Q3 		$13.6M Sell
854,511
-196,100
-19% -$2.71M ﹤0.01% 1835
2017
Q2 		$12.7M Sell
1,050,611
-1,072,495
-51% -$11.4M ﹤0.01% 1856
2017
Q1 		$44.1M Sell
2,123,106
-179,391
-8% -$2.81M 0.01% 1367
2016
Q4 		$32.9M Buy
2,302,497
+1,272,697
+124% +$19.4M ﹤0.01% 1485
2016
Q3 		$16.9M Sell
1,029,800
-1,281,497
-55% -$18.5M ﹤0.01% 1755
2016
Q2 		$33M Buy
2,311,297
+116,500
+5% +$1.57M ﹤0.01% 1452
2016
Q1 		$31.8M Buy
+2,194,797
New +$31.5M ﹤0.01% 1444

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments's CRVS Position: Q2 2026 in Review

Fidelity Investments reduced its Corvus Pharmaceuticals (CRVS) stake by 34% in Q2 2026, selling an estimated $16.7K and leaving 2,356 shares worth $35.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4452.

Fidelity Investments first reported a position in CRVS in Q1 2016 and has held it in 27 quarters since. The position peaked at $44.1M in Q1 2017. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Fidelity Investments held 2,356 shares of Corvus Pharmaceuticals worth $35.2K as of Q2 2026.
  • Fidelity Investments sold 1,205 Corvus Pharmaceuticals shares in Q2 2026, an estimated $16.7K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4452 holding.
  • Fidelity Investments first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 27 quarters since.
  • Fidelity Investments's Corvus Pharmaceuticals position peaked at $44.1M in Q1 2017.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.